News & Media :: Vedanta Biosciences, Inc.

Oct 5, 2021

Vedanta Announces Positive Topline Phase 2 Data for VE303 in High-Risk C. difficile Infection and Exercise of $23.8 Million Option by BARDA

Recent News

Jul 21, 2021

Vedanta Biosciences Completes $68 Million Series D Financing

Jun 29, 2021

Vedanta Biosciences Presents New Data from Phase 1 Study of VE202, Its Rationally-Defined Consortium for the Treatment of Inflammatory Bowel Disease, at the International Human Microbiome Consortium Congress 2021 (IHMC)

Jun 17, 2021

CARB-X 5th Anniversary -- Highlights from the portfolio

Apr 29, 2021

Vedanta Biosciences to Present at the SVB Leerink Biopharma Private Company Connect Event

View All News View All Press Releases